Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 1401Neoplasms 1128Prostatic Neoplasms 745Lung Neoplasms 621Colorectal Neoplasms 599Carcinoma, Non-Small-Cell Lung 570Carcinoma, Hepatocellular 414Pancreatic Neoplasms 402Leukemia, Myeloid, Acute 398Stomach Neoplasms 356Multiple Myeloma 326Brain Neoplasms 311Ovarian Neoplasms 310Head and Neck Neoplasms 290Neoplasm Metastasis 275Precursor Cell Lymphoblastic Leukemia-Lymphoma 260Rectal Neoplasms 254Uterine Cervical Neoplasms 248Recurrence 248Melanoma 243Esophageal Neoplasms 237Glioblastoma 232Squamous Cell Carcinoma of Head and Neck 231Lymphoma 214Sarcoma 209Urinary Bladder Neoplasms 192Colonic Neoplasms 192Glioma 191Triple Negative Breast Neoplasms 188Hematologic Neoplasms 182

Interventions

Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × OTHER × Myeloid Malignancy × Clear all
NCT07263074 2026-03-30

CHORDS

University of Rochester

Phase NA Recruiting
120 enrolled

Myeloid Malignancy

NCT03850418 2026-02-24

Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant

Henry Ford Health System

Phase 2 Recruiting
43 enrolled

Myeloid Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡